KD 101

Drug Profile

KD 101

Alternative Names: KD101

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator Kwang Dong Pharmaceutical
  • Class Obesity therapies; Sesquiterpenes; Small molecules; Terpenes
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Obesity

Most Recent Events

  • 28 Jun 2016 Seoul National University Hospital plans a phase I trial in Healthy volunteers in South Korea (PO) (NCT02819934)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2015 Phase-I clinical trials in Obesity in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top